News and events
Find out the latest news and updates about the regulation of therapeutic goods in Australia, as well as events, webinars and consultations with the community.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
Industry notices and compliance undertakings
Notifications for sponsors, manufacturers, and advertisers about official decisions and new or updated regulatory requirements, as well as information about recent regulatory compliance and enforcement actions.
-
Regulatory decision notices
Access official regulatory decisions for sponsors, manufacturers and advertisers, including GMP clearances, listing notices, administrative instruments, and updates to regulatory requirements. -
Latest articles
-
Upgrade of TGA’s internal database for medicine adverse events reports
The Adverse Event Management System (AEMS) has moved to the cloud, delivering improved system stability and security. -
Prime Medic Group issued infringement notices for alleged unlawful advertising of weight loss medicines
TGA has issued infringement notices to Prime Medic Group Pty Ltd (Prime Medic) and an individual for the alleged unlawful advertising of weight loss medicines in contravention of the Therapeutic Goods Act 1989 (the Act). -
TGA issues infringement notices to 6 individuals for alleged importation and unlawful advertising of therapeutic goods
We have issued 11 infringement notices totalling $43,560, to 6 individuals, for the alleged importation and unlawful advertising of therapeutic goods.
Latest publications
-
Advisory Committee on Complementary Medicines meeting statement for 6 November 2025
-
This web publication constitutes a notice for the purposes of regulation 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Find out about the public submissions on scheduling matters referred to the ACMS
Latest consultations
-
We are seeking feedback on proposed changes to Australian medicine labelling rules.
-
We are seeking feedback on proposed amendments relating to transparency of disruptions to supply of a medical device.
-
We are seeking input from stakeholders responsible for developing, deploying or supplying Digital Mental Health Tools (DMHT) to help us better understand these tools.